Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Income
$5.3M
Filings
182
Unique Clients
9
Active Period
1999–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Access to Life-Saving Medicine Act
2007 · mid_year · Client: TEVA PHARMACEUTICALS USA
Generic biologic drug pathway, H.R. 1038, "The Access to Lifesaving Medicine Act."
Client expense: — · Firm income: —
Matched citations: H.R. 1038
Access to Life-Saving Medicine Act
2007 · mid_year · Client: TEVA PHARMACEUTICALS USA
Generic biologic drug pathway, H.R. 1038, "The Access to Lifesaving Medicine Act."
Client expense: — · Firm income: —
Matched citations: H.R. 1038
Commodity Exchange Reauthorization Act of 2005
2006 · year_end · Client: FUTURES INDUSTRY ASSOCIATION
S. 1566 introduced July 29, 2005, CFTC Reauthorization House Reauthorization Legislation SRO Governance Rules Defining located outside U.S.
Client expense: — · Firm income: $200,000
Matched citations: S. 1566
Source: Senate LDA